Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Hologic, Inc. (NASDAQ: HOLX).

Full DD Report for HOLX

You must become a subscriber to view this report.


Recent News from (NASDAQ: HOLX)

Hologic Launches Three-in-One Omni(TM) Hysteroscope
Flexible, modular design with powerful visualization gives doctors a single device with three sheath options to both diagnose and treat patients Hologic, Inc. (Nasdaq: HOLX) announced today the U.S. launch of its Omni™ hysteroscope , an innovative three-in-one modular scope wi...
Source: Business Wire
Date: December, 10 2018 08:07
Hologic (HOLX) Q4 2018 Results - Earnings Call Transcript
Hologic, Inc. (HOLX) Q4 2018 Earnings Call November 07, 2018 4:30 pm ET Executives Michael J. Watts - Hologic, Inc. Stephen P. MacMillan - Hologic, Inc. Karleen Marie Oberton - Hologic, Inc. Analysts Raj Denhoy - Jefferies LLC Isaac Ro - Goldman Sachs & Co. LLC Tych...
Source: SeekingAlpha
Date: November, 07 2018 22:06
Hologic misses by $0.01, beats on revenue
Hologic (NASDAQ: HOLX ): Q4 Non-GAAP EPS of $0.58 misses by $0.01 ; GAAP EPS of $0.18 misses by $0.17 . Revenue of $813.5M (+1.3% Y/Y) beats by $6.98M . Shares -1.8% . Press Release More news on: Hologic, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 07 2018 16:59
Hologic fiscal Q4 top line up 1%; earnings down 39%
Hologic (NASDAQ: HOLX ) fiscal Q4 results ($M): Revenues: 813.5 (+1.3%); Breast Health: 322.2 (+7.1%). More news on: Hologic, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: November, 07 2018 16:21
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2018
– Revenue of $813.5 Million Grows 1.3%, 1.7% in Constant Currency – – Company Posts GAAP Diluted EPS of $0.18, Non-GAAP Diluted EPS of $0.58 – – Company Expects Solid Revenue and EPS Growth in Fiscal 2019 – Hologic, Inc. (Nasdaq: HOLX) ann...
Source: Business Wire
Date: November, 07 2018 16:01
Notable earnings after Wednesday's close
AAOI , ADT , ALB , ALRM , AMBC , ANGI , ANSS , ARNA , ATO , AVID , AVLR , AYX , BREW , CABO , CARG , CASA , CISN , CSGS , CSOD , CTRP , CVNA , CYBR , DVA , ECPG , EDIT , ENS , ENV , ET , EVC , EVRG , FARM , FG , FLO , FLS , FOSL , GDOT , GKOS , HK , HO...
Source: SeekingAlpha
Date: November, 06 2018 17:35
Hologic to Webcast Presentation at the Stifel 2018 Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13 at 8 a.m. Eastern Time. The presentation will be webcast live and may be accessed through a link on the investors section of Hologic...
Source: Business Wire
Date: November, 06 2018 16:05
Tracking Kahn Brothers Portfolio - Q3 2018 Update
This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers’ 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers’ regulatory 13F Form filed on 10/30/2018. Please visit our Tracking Kahn Brothers Portfolio series t...
Source: SeekingAlpha
Date: November, 01 2018 04:35
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Hologic, Inc.
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces it has commenced an investigation of Hologic, Inc. (“Hologic” or “the Company”) (NASDAQGS: HOLX) concerning possible violations of federal securities laws. Hologic is the parent company o...
Source: GlobeNewswire
Date: September, 13 2018 17:49
Premarket analyst action - healthcare
CytomX Therapeutics (NASDAQ: CTMX ) initiated with Buy rating and $32 (68% upside) price target at H.C. Wainwright citing bullish prospects for Probody platform. More news on: CytomX Therapeutics, Rocket Pharmaceuticals, Inc., ObsEva, Healthcare stocks news, Stocks on the move, , Read ...
Source: SeekingAlpha
Date: September, 13 2018 08:28

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1438.7039.4639.8438.702,378,032
2017-07-2045.4045.4145.5445.071,990,874
2017-07-1945.0145.2845.3344.8152,259,133
2017-07-1844.5944.9544.9844.311,649,741
2017-07-1745.1944.6145.4744.492,992,880

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14119,292241,05149.4883Short
2018-12-13129,464264,23048.9967Short
2018-12-12113,426251,68445.0668Short
2018-12-11102,860195,77752.5394Short
2018-12-10199,206349,44657.0062Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HOLX.


About Hologic, Inc. (NASDAQ: HOLX)

Logo for Hologic, Inc. (NASDAQ: HOLX)

Not available

 

Contact Information

 

 

Current Management

  • Glenn P. Muir / CFO

Current Share Structure

  • Market Cap: $10,565,523,378 - 05/16/2018
  • Issue and Outstanding: 273,010,940 - 04/27/2018

 



Daily Technical Chart for (NASDAQ: HOLX)

Daily Technical Chart for (NASDAQ: HOLX)


Stay tuned for daily updates and more on (NASDAQ: HOLX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: HOLX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HOLX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HOLX and does not buy, sell, or trade any shares of HOLX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/